Liver Failure - Pipeline Review, Q3 2011
Global Markets Direct’s, 'Liver Failure - Pipeline Review, Q3 2011', provides an overview of the Liver Failure therapeutic pipeline. This report provides information on the therapeutic development for Liver Failure, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Liver Failure. 'Liver Failure - Pipeline Review, Q3 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Liver Failure.
- A review of the Liver Failure products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Liver Failure pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Liver Failure.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies
Liver Failure – Pipeline Review, Q3 2011 Liver Failure - Pipeline Review, Q3 2011 Reference Code: GMDHC1161IDB Publication Date: July 2011 Liver Failure – Pipeline Review, Q3 2011 GMDHC1161IDB / Pub July 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1) Liver Failure – Pipeline Review, Q3 2011 Ta b le o f Co n te n ts Table of Contents 2 List of Tables 3 List of Figures 3 Introduction 4 Global Markets Direct Report Coverage 4 Liver Failure Overview 5 Therapeutics Development 6 An Overview of Pipeline Products for Liver Failure 6 Liver Failure Therapeutics under Development by Companies 8 Liver Failure Therapeutics under Investigation by Universities/Institutes 9 Late Stage Products 10 Comparative Analysis 10 Mid Clinical Stage Products 11 Comparative Analysis 11 Pre-Clinical Stage Products 12 Comparative Analysis 12 Liver Failure Therapeutics - Products under Development by Companies 13 Liver Failure Therapeutics - Products under Investigation by Universities/Institutes 14 Companies Involved in Liver Failure Therapeutics Development 15 Angion Biomedica Corp. 15 Liver Failure - Therapeutics Assessment 16 Assessment by Monotherapy Products 16 Assessment by Route of Administration 17 Assessment by Molecule Type 19 Drug Profiles 21 N-Acetylcysteine - Drug Profile 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Allogenic Bone Marrow Stem Cells Transplant - Drug Profile 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Umbilical Cord Mesenchymal Stem Cells - Drug Profile 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 ALF-5755 - Drug Profile 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Liver Failure - Featured News 25 Mar 16, 2011: Digna Biotech And Biotecnol Receive Spanish Approval For Phase I Clinical Studies Of Cardiotrophin I 25 Mar 10, 2011: Digna Biotech And Biotecnol
Pages to are hidden for
"Liver Failure - Pipeline Review, Q3 2011"Please download to view full document